(Q39521376)

12 September 2017

title

Clinical trials evaluating pathogen-reduced platelet products: methodologic issues and recommendations (English)

1 reference

12 September 2017

Richard J Cook

1

1 reference

12 September 2017

Nancy M Heddle

series ordinal

2

1 reference

12 September 2017

publication date

12 November 2012

1 reference

12 September 2017

1 reference

12 September 2017

volume

53

1 reference

12 September 2017

issue

8

1 reference

12 September 2017

page(s)

1843-1855

1 reference

Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03951.X

Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03951.X

A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03951.X

Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03951.X

A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03951.X

Controversy in Counting and Attributing Events in Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03951.X

The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03951.X

A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03951.X

Dose of prophylactic platelet transfusions and prevention of hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03951.X

Methods for the analysis of bleeding outcomes in randomized trials of PLT transfusion triggers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03951.X

The definition of refractoriness to platelet transfusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03951.X

Assessing the effectiveness of whole blood-derived platelets stored as a pool: a randomized block noninferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03951.X

Time to rethink clinically important outcomes in platelet transfusion trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03951.X

Surrogate endpoints in clinical trials: definition and operational criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03951.X

A new tool to assess bleeding severity in patients with chemotherapy-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03951.X

Design of clinical trials to evaluate the efficacy of platelet transfusion: the euroSPRITE trial for components treated with Helinx technology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03951.X

Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03951.X

Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03951.X

Rationale for randomized controlled trials and for intention-to-treat analysis in transfusion medicine: are they one and the same?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03951.X

Cox's Regression Model for Counting Processes: A Large Sample Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03951.X

10.1111/J.1537-2995.2012.03951.X

21 January 2018

Identifiers

DOI

1 reference

12 September 2017

1 reference